John M. Vierling

EFFICACY AND SAFETY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AND COMPENSATED CIRRHOSIS IN THE PHASE 3 PLACEBO-CONTROLLED RESPONSE TRIAL

Alejandra Villamil, Ziad H Younes, Christopher L. Bowlus, John M. Vierling et autres

In the Phase 3 RESPONSE trial (NCT04620733), seladelpar, a first-in-class delpar (selective peroxisome proliferator–activated receptor delta agonist), significantly improved biomarkers of cholestasis in patients with primary biliary cholangitis (PBC) over 12 months vs placebo. More patients with cirrhosis met the primary endpoint …

ar, us, cz, it, nl (code pays fourni par la source)

532: EFFICACY AND SAFETY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AND COMPENSATED CIRRHOSIS IN THE PHASE 3 PLACEBO-CONTROLLED RESPONSE TRIAL

Alejandra Villamil, Ziad H Younes, Christopher L. Bowlus, John M. Vierling et autres

Mo1610: IMPACT OF ELAFIBRANOR ON MARKERS OF DISEASE ACTIVITY AND PROGRESSION IN PATIENTS WITH ADVANCED PRIMARY BILIARY CHOLANGITIS

Kris V. Kowdley, Christopher L. Bowlus, Marlyn J. Mayo, John M. Vierling et autres

A virtual scalable model of the Hepatic Lobule for acetaminophen hepatotoxicity prediction

Stelian Camara Dit Pinto, Jalal Cherkaoui, Debarshi Ghosh, Valentine Cazaubon et autres

Addressing drug-induced liver injury is crucial in drug development, often causing Phase III trial failures and market withdrawals. Traditional animal models fail to predict human liver toxicity accurately. Virtual twins of human organs present a promising solution. We introduce the Virtual Hepatic …

us, fr (code pays fourni par la source)

Fazirsiran for Adults With Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA)

Virginia Clark, Charlie Strange, Pavel Strnad, Antonio J. Sanchez et autres

BACKGROUND & AIMS: Homozygous ZZ alpha-1 antitrypsin (AAT) deficiency produces mutant AAT (Z-AAT) proteins in hepatocytes, leading to progressive liver fibrosis. We evaluated the safety and efficacy of an investigational RNA interference therapeutic, fazirsiran, that degrades Z-AAT messenger RNA, reducing deleterious protein …

us, de, pt, nl, it, es (code pays fourni par la source)